Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, Dec. 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that clinical data of IBI188 (anti-CD47 monoclonal antibody) as first-line treatment in newly diagnosed higher risk myelodysplastic syndrome (MDS)...
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 11, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and...
Goodwin Biotechnology Inc. is now GBI, as Part of their Rebranding Initiative on their 30-Year Anniversary!
PLANTATION, Fla., Dec. 10, 2022 /PRNewswire/ -- Goodwin Biotechnology, Inc. announces its new name, GBI, as part of a rebranding initiative to commemorate its 30-year anniversary. This includes a new name, logo and website to reflect its evolution from an early-stage clinical manufacturing Contract Development and Manufacturing Organization (CDMO) to a commercial...
Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that data presented on the ongoing CFI-402257-CL-001 clinical study of the Company's CFI-402257 program in advanced solid tumors, continued to show a tolerable safety profile and demonstrated clinical benefit both as a monotherapy as well in combination...
The 1st Boao International Conference on Real World Studies of Medical Products Held in Hainan
HAIKOU, China, Dec. 9, 2022 /PRNewswire/ -- On December 8, the first Boao International Conference on Real World Studies of Medical Products was held in Hainan Province, with the theme of "Real World Data Studies and Innovative Development and Supervision of Medical Products". The 1st Boao International Conference on Real World Studies of Medical Products...
SmartCardia Earns Frost & Sullivan’s 2022 Global New Product Innovation Award in the Cardiac-monitoring Wearables Industry
The company's innovative real-time monitoring system ensures that patients are treated effectively and efficiently. SAN ANTONIO, Dec. 9, 2022 /PRNewswire/ -- Based on its recent analysis of the cardiac-monitoring wearables market, Frost & Sullivan recognizes SmartCardia with the 2022 Global New Product Innovation Award for its groundbreaking patch that records and transmits 7 lead ECG, heart rate, respiration rate, oxygen...
CGTN: What has China done in its nearly 3 years of COVID-19 fight?
BEIJING, Dec. 9, 2022 /PRNewswire/ -- It's been nearly three years since China launched the fight against COVID-19. During that time, China's relentless efforts protected its people and provided valuable experiences for the world. The efforts also bought precious time to develop a scientific way to analyze and control the virus in the world's most populated country. People's lives...
A Successful Conclusion of CamTech Summit Powered by Prudential Cambodia 2022
PHNOM PENH, Cambodia , Dec. 9, 2022 /PRNewswire/ -- Cambodian Association of Finance and Technology (CAFT), the National Bank of Cambodia (NBC), The Association of Banks in Cambodia (ABC) and Cambodia Microfinance Association (CMA) with Prudential Cambodia as its Title Sponsor successfully concluded the month-long CamTech Summit Powered by Prudential last December 02, 2022 at the Royal Train Station, Phnom Penh...
Shenzhen Holds 2022 Global Investment Promotion Conference to Build a Magnet for International Investors
SHENZHEN, China, Dec. 9, 2022 /PRNewswire/ -- Shenzhen welcomes outstanding investors from all over the world. The 2022 Shenzhen Global Investment Promotion Conference will be held in Shenzhen, China on December 9. A number of major projects in the fields of information technology, artificial intelligence, biotechnology, new energy, new materials, high-end equipment, and environment protection will be signed to...
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors
Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting the Tumor Associated Antigen (TAA) Claudin 18.2 The Phase I trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 as a monotherapy in patients with advanced or metastatic solid tumors SHANGHAI and HONG KONG, Dec....
